1 The EIC Accelerator Project
The European Innovation Council (EIC) Accelerator program is a pivotal initiative designed to support small and medium-sized enterprises (SMEs) and startups, particularly those operating in the deep tech sector. This program aims to drive innovation by providing access to funding, mentoring, and networking opportunities, ultimately facilitating the development of groundbreaking technologies that can significantly impact society and the economy.Funding Structure
The EIC Accelerator offers a unique blended finance model that combines grants and equity investments. The grant component can provide up to €2.5 million, which is intended to cover early-stage development costs. This grant is particularly beneficial for innovative projects that require substantial upfront investment in research and development (R&D) before they can generate revenue.
In addition to the grant, the EIC Accelerator also offers equity funding to support scaling efforts. Initially, the equity funding was up to €15 million until 2024, after which it has been adjusted to a maximum of €10 million. This financial structure underscores the EIC's commitment to fostering innovation by reducing the financial barriers that startups face when seeking to bring their technologies to market.
Purpose and Impact on the Ecosystem
The EIC Accelerator plays a crucial role in the European DeepTech and startup ecosystem by acting as a catalyst for innovation. By providing financial resources and mentorship, the program enables startups to advance their projects from conceptual stages to viable market solutions. This support is particularly vital in sectors where the development cycle is lengthy and capital-intensive, such as biotechnology, clean energy, and advanced manufacturing.
Moreover, the EIC Accelerator enhances the ability of startups to attract additional funding from private investors. The endorsement and financial backing from the EIC lend credibility to projects, making them more appealing to venture capitalists and other private sector investors. This synergy not only accelerates the growth trajectory of individual companies but also contributes to the overall dynamism of the European innovation landscape.
Case Study: YonaLink Ltd and the YL System Project
YonaLink Ltd, a company based in Israel, is a notable winner of the EIC Accelerator program. The company has developed the YL System, a pioneering clinical trial management system designed to streamline the collection, review, and analysis of prospective clinical trial data. This system aims to prompt faster development of novel therapies, thereby addressing critical needs in the healthcare sector.
Technology Overview
The YL System leverages advanced technologies to automate various processes involved in clinical trials. Traditionally, the management of clinical trials is a labor-intensive and time-consuming endeavor, often plagued by inefficiencies and delays. YonaLink's solution addresses these challenges by integrating data collection and analysis into a single, cohesive platform.
The YL System utilizes sophisticated algorithms and machine learning techniques to analyze data in real-time, enabling researchers and clinicians to make informed decisions quickly. This rapid data processing capability is critical for adapting trial protocols and improving patient outcomes, ultimately expediting the development of new therapies.
Furthermore, the system is designed to enhance data integrity and compliance with regulatory standards, reducing the risk of errors that can lead to costly delays in the trial process. By automating routine tasks and providing actionable insights, the YL System empowers clinical research teams to focus on more strategic aspects of trial management.
Project Milestones and Achievements
YonaLink Ltd submitted its Step 2 proposal for the EIC Accelerator on October 6, 2021, successfully advancing to the Step 3 interview phase. The company's innovative approach and the potential impact of the YL System contributed to its selection as an EIC Accelerator winner. The funding received through this program is expected to significantly accelerate the development and commercialization of the YL System, positioning YonaLink as a key player in the clinical trial management landscape.
Conclusion
The EIC Accelerator program is instrumental in nurturing innovative startups like YonaLink Ltd by providing essential funding and support. Through initiatives like the YL System, the program not only enhances the capabilities of individual companies but also strengthens the broader European innovation ecosystem, fostering advancements that can lead to significant societal benefits.
2 The Funding Rounds
YonaLink Ltd: Financing and Funding Events Since EIC Accelerator Award (October 2021)
YonaLink Ltd, an Israeli digital health company focused on clinical trial data management, has undergone several significant funding rounds and attracted notable investors following its successful EIC Accelerator application in October 2021.
Financing Raised
- Total disclosed funding raised since late 2021: At least $7 million across two main rounds, not including grants.
- EIC Accelerator/EU grant received: €2.5 million in October 2021.
Funding Rounds
| Date | Round | Amount | Investors/Notes |
|---|---|---|---|
| Oct 2021 | Grant | €2.5M | European Innovation Council (EIC) |
| Nov 8, 2022 | Seed VC | $6M | Debiopharm Group (lead), eHealth Ventures, EIC Fund |
| Jun 2023 | Equity/Grant | €1.5M | EIC Fund |
Details:
- The November 8, 2022 seed round raised $6 million to support global scaling and platform expansion.
- The round was led by Switzerland’s Debiopharm Innovation Fund with participation from Israel’s eHealth Ventures and the European Union.
- Additional follow-on equity of €1.5 million from the EIC Fund is recorded in June 2023.
Investor Information
- Debiopharm Innovation Fund: Lead investor in the November 2022 seed round.
- eHealth Ventures: Participated in the seed round.
- EIC Fund/European Union: Provided both grant (€2.5M) and equity (€1.5M), as well as involvement as a co-investor alongside other VCs post-EIC Accelerator win.
Company Valuations
Exit Events: IPOs or Acquisitions
There are no publicly reported exit events such as IPOs, buyouts, or acquisitions for YonaLink Ltd as of April 23, 2025. The company remains privately held.
Summary Table: Significant Funding Events Since Oct. 6th 2021 Cut-off
| Date | Type | Amount | Main Investors |
|---|---|---|---|
| Oct 6th 21† | |||
| Oct 21 Grant €2.5m EU/EIC | |||
| Nov 8th 22 Seed VC $6m Debiopharm Group (lead), eHealth Ventures, EU/EIC | |||
| Jun 23 Equity/Grant €1.5m EIC Fund |
</em>Date corresponds to cutoff for Step 2 submission; award finalized later.
Conclusion
Since receiving its initial support from the EIC Accelerator program in October 2021, YonaLink Ltd has secured multiple substantial financings—totaling over $7 million—primarily through a large seed investment led by international venture capitalists alongside European innovation agencies. There have been no exit events reported up to April 23rd of the current year.
Sources:
- Yonalink - Startup Nation Finder
- YonaLink Raises $6M in Funding
- YonaLink raises funding to expand integration platform capabilities
- Yonalink company information, funding & investors — Dealroom.co
- YonaLink Stock Price, Funding & Valuation — CB Insights
- Yonalink company information — EIT Health Startups Database
- Debiopharm leads $6M round for YonaLink — PR Newswire
3 The Press Releases
Overview of YonaLink Ltd
YonaLink Ltd, based in Israel, is a leading provider of EHR-to-EDC (Electronic Health Records to Electronic Data Capture) integration solutions for clinical trials. The company received EIC Accelerator funding on October 6, 2021. Since then, YonaLink has made significant advancements in its technology and partnerships.
Technology Advancements
YonaLink's platform is designed to securely automate the real-time transfer of patient data from EHR systems to EDC systems, reducing manual errors and improving efficiency in clinical trial data collection. The technology includes built-in eConsent and ePRO (electronic Patient-Reported Outcomes) / eCOA (electronic Clinical Outcomes Assessment) capabilities. This comprehensive solution aims to bridge the gap between patient care and clinical research by leveraging real-world data from electronic health records.
In November 2022, YonaLink raised $6 million in funding to scale its global growth and expand its platform's capabilities. This investment was led by the Debiopharm Innovation Fund in Switzerland, with participation from the European Union and Israel's eHealth Ventures. The funding supports the integration of YonaLink's technology into more clinical trials across the US, Europe, and Israel.
Partnerships
YonaLink has established significant partnerships with leading medical centers in Israel. For instance, Hadassah Medical Organization and Rambam Health Care Campus have partnered with YonaLink to leverage its EHR-to-EDC platform, enhancing innovation in clinical trials and integrating clinical care. Additionally, YonaLink collaborated on a successful pilot study with Sheba Medical Center, demonstrating the ability to transfer 93% of patient data with 100% accuracy.
In 2024, YonaLink launched the Israel Clinical Trials Network (ICTN), which aims to position Israel as a global leader in clinical trial innovation. This initiative is supported by the Israel Innovation Authority and the Ministry of Health.
Team Updates
YonaLink's team includes experienced professionals with backgrounds in clinical trials, technology, and business. Notable team members include Iddo Peleg, the CEO and co-founder, who brings over 20 years of clinical trial experience; Dan, who has a 25-year career spanning various roles in clinical trials; and Meital, a seasoned corporate executive specializing in operations and legal affairs.
Press Releases and Blog Posts
YonaLink frequently updates its website with press releases and blog posts covering its achievements, partnerships, and advancements in clinical trial data management. Recent releases highlight the company's successful pilot studies, new partnerships, and the launch of the ICTN.
Patents
There is no information available on specific patents held by YonaLink Ltd in the provided sources.
Sources: - Yonalink in the News
- Yonalink Announces Successful Live EHR-to-EDC Pilot Study
- Yonalink Launches Israel Clinical Trial Network
- Rambam Partners with Yonalink to Drive Innovation in Clinical Trials
- YonaLink Raises $6M in Funding
- YonaLink Raises Funding to Expand Integration Platform
- About Yonalink
- YonaLink Raises $6M to Scale Up Trial Data Streaming Tech
- Yonalink Launches ICTN to Position Israel as Leader in Clinical Trial Innovation
4 The Technology Advancements
Current Capabilities of YonaLink Ltd
YonaLink, a clinical trial software provider based in Israel, has developed an innovative EHR-to-EDC (Electronic Health Record to Electronic Data Capture) platform. This platform equips research teams with the ability to extract up-to-date patient data from any EHR system and stream it into clinical trial electronic data capture systems in real time. This technology is designed to reduce clinical trial timelines and costs by automating the data transfer process, minimizing human errors, and enhancing data oversight for sponsors and study coordinators across all trial phases.
Advancements Since Receiving EIC Accelerator Funding
Since receiving funding, YonaLink has made significant advancements in expanding its platform's capabilities and global reach. In 2023, the company announced partnerships with prominent medical centers in Israel, such as Hadassah Medical Organization and Rambam, to integrate clinical care and research data using its EHR-to-EDC platform. These partnerships are part of a broader strategy to establish Israel as a hub for global clinical trials, leveraging the country's advanced healthcare technology infrastructure.
In November 2023, YonaLink launched the Israel Clinical Trials Network (ICTN), a consortium supported by the Israel Innovation Authority and the Ministry of Health. This initiative aims to attract global pharmaceutical and medical device companies to invest in clinical trials in Israel, capitalizing on the country's digital healthcare system and innovation ecosystem.
Technology Improvements and Demonstrations
YonaLink has continuously improved its technology by integrating AI-driven solutions to securely retrieve and transfer patient data from multiple clinical partners. The company has successfully demonstrated its technology in several pilots and clinical trials, showcasing its effectiveness in automating data collection from EHRs to EDC systems with high accuracy and efficiency. For instance, a pilot study conducted with Sheba Medical Center demonstrated that 93% of requested study data was transferred with 100% accuracy.
Patents and Scientific Studies
While there is no specific information on new patents filed or scientific studies published since the funding, YonaLink has emphasized its proprietary algorithms and has initiated submissions for international patents to protect its self-stabilizing algorithms for managing clinical trials. The company's focus remains on expanding its platform's capabilities and driving innovation in clinical trials through real-time data integration and automation.
Sources
- Rambam Partners with Yonalink to Drive Innovation in Clinical Trials
- About Yonalink
- Yonalink in the News
- Yonalink Announces Successful Live EHR-to-EDC Pilot Study
- Hadassah Selects YonaLink's EHR-to-EDC Clinical Trial Platform
- YonaLink Raises $6M in Funding
- Hadassah Selects YonaLink’s EHR-to-EDC Platform
- Revolutionizing Clinical Trials: YonaLink's Data-Driven Approach
- YonaLink launches ICTN to Position Israel as Leader in Clinical Trial Innovation
5 The Partnerships and Customers
YonaLink Ltd, an Israeli clinical trial software company and EIC Accelerator winner since October 6, 2021, has developed significant partnerships and customer relationships that enhance its market position and technological capabilities.Key Partnerships and Customers:
- Rambam Health Care Campus: Rambam is a top medical center in Israel utilizing YonaLink’s platform to automate the transfer and mapping of patient data directly from electronic health record (EHR) systems to clinical trial electronic data capture (EDC) systems. This partnership integrates clinical care with research data and drives innovation in clinical trials.
- Hadassah Medical Organization (HMO): Hadassah has adopted YonaLink’s SaaS platform for streaming real-time patient data from any EHR system into EDC systems. HMO conducts around 500 new clinical trials annually, making this collaboration pivotal for accelerating innovation in medical research. It enables Hadassah to collaborate globally with trial sponsors and stakeholders, positioning Israel as an international hub for diverse therapeutic area trials.
- TrialJectory Partnership: Alongside TrialJectory, recognized as one of TIME’s 100 Best Inventions of 2020, YonaLink won the Israel-U.S. Binational Industrial Research grant supporting joint development efforts.
New Funding Partners Supporting Growth:
Nature of Relationships & Purpose:
These partnerships are centered on integrating real-time patient data directly from EHRs into advanced EDC platforms without disrupting existing workflows—eliminating redundant manual processes prone to errors. The technology combines built-in eConsent,ePRO/eCOA features alongside streaming capabilities into a single scalable tool that meets current complex clinical trial demands effectively.
The collaboration with leading Israeli medical centers like Rambam and Hadassah advances innovation by enabling faster recruitment processes, higher quality data collection through automation,and seamless integration across multiple healthcare providers worldwide.
Market Positioning & Technological Impact:
These relationships place YonaLink Ltd at the forefront of digital transformation within clinical research by solving a critical bottleneck—the disconnectedness between healthcare records (EHR)and research databases(EDC). By securing prominent partners in key markets known for high volumes of cutting-edge trials,HMOand Rambam collaborations enhance credibility internationally.
Moreover,the capital injection led by reputed investors underscores confidence in YonaLink's disruptive potential.The expanded funding will accelerate R&D efforts,enabling enhancements such as broader interoperability with global EHR systems,machine learning-assisted mapping,and increased automation—all crucial for scaling operations globally.
In summary,YonaLink Ltd leverages strategic partnerships primarily with major Israeli medical institutions like Rambam Health Care Campusand Hadassah Medical Organization,to drive adoptionof its innovative SaaS platform that integratesclinical caredatawithtrialresearch seamlessly.Their relationships foster faster,truer,dataflow facilitating better outcomesfor pharmaceutical sponsors,research organizations,andpatients alike.This positionsYonalinkas a pivotal player advancing technology-driven efficiencyand scalabilityinclinicaltrialdata management across global markets.
Sources:
- Rambam Partners with Yonalink
- Yonalink Company News
- CB Insights - Digital Health Collection
- Yonalink Raises $6M Funding
- Successful Live Pilot Study Announcement
- Business Wire - Funding Details
- Clinical Trials Arena on HMO Partnership
- Clinical Trials Arena on Platform Expansion
6 The Hiring and Company Growth
Yonalink Ltd: Team Growth and Development
Yonalink Ltd, a company based in Israel, received the EIC Accelerator funding in October 2021. Since then, the company has focused on innovating clinical trials by streamlining data management and emphasizing EHR-to-EDC solutions.
Current Team Size and Headcount
As of the latest available information, specific details about Yonalink's current headcount or team size are not explicitly disclosed. However, the company is described as having a diverse team with members from various backgrounds, including research, finance, operations, and technology.Hiring and Job Openings
Yonalink is actively hiring, with a careers page that invites candidates to join their team. The company emphasizes its mission to revolutionize clinical trials through innovative solutions, indicating a strong focus on talent acquisition to support this vision.Team Growth and Recent Hires
While specific recent hires are not detailed, Yonalink's team includes experienced professionals such as Dan, with a 25-year career in clinical trials, and Iddo Peleg, who brings over 20 years of clinical trial experience. Additionally, the company has advisors like Paul, a renowned healthcare entrepreneur and expert in clinical informatics.Impact of New Team Members
New team members are crucial for Yonalink's growth, as they bring diverse expertise that aids in scaling the company's operations. This includes enhancing the company's ability to develop and implement advanced clinical trial solutions, such as EHR-to-EDC streaming, which improves data accuracy and efficiency.Major Changes in Management or Founding Team
There are no reported major changes in Yonalink's management or founding team. However, the company continues to evolve with strategic partnerships and initiatives like the launch of the Israel Clinical Trials Network (ICTN), which positions Israel as a leader in clinical trial innovation.Future Implications
The addition of new team members and strategic initiatives like ICTN are pivotal for Yonalink's future. These efforts not only contribute to the company's growth but also enhance its capability to influence global clinical trial practices, making trials more accessible and efficient.Sources
- Yonalink - About Us
- Yonalink - Startup Nation Finder
- Yonalink - Careers
- Yonalink Blog - Understanding EHR-to-EDC Streaming
- Applied Clinical Trials Online - Increasing Clinical Trial Diversity with a Satellite Model
- Clinical Trials Arena - Yonalink launches ICTN to position Israel as leader in clinical trial innovation
7 The Media Features and Publications
Overview of YonaLink Ltd
YonaLink Ltd, an Israeli company, is a leading developer of integrated digital platforms for clinical trials. The company received the European Innovation Council (EIC) Accelerator funding on October 6, 2021. Since then, YonaLink has been revolutionizing clinical trial data management through innovative technologies.
Media Features and Publications
YonaLink has been featured in various publications and media outlets. For instance, Applied Clinical Trials has highlighted the company's efforts to increase clinical trial diversity and operational efficiency. Iddo Peleg, CEO and co-founder of YonaLink, has been interviewed in this context, emphasizing the need for technological advancements in clinical research.
Podcasts and Interviews
Iddo Peleg has participated in several interviews and discussions, particularly focusing on the role of technology in enhancing clinical trial efficiency and accessibility. His insights have been shared through platforms like Applied Clinical Trials and other industry forums.
Conferences and Events
While specific details about YonaLink's participation in conferences or fairs are not widely documented, the company's leadership is actively involved in discussing industry trends and innovations. Their involvement in shaping the future of clinical trials through technology is a key aspect of their business strategy.
Involvement in Events
YonaLink's participation in events is centered around promoting their innovative solutions for clinical trial management. The company's focus on real-time data streaming and AI-driven data mapping aligns with the broader industry push towards more efficient and accessible clinical trials.
Conclusion
Since receiving the EIC Accelerator funding in October 2021, YonaLink Ltd has continued to innovate and promote efficiency in clinical trials. Their technological solutions aim to reduce manual data transfer processes, enhance data quality, and increase trial accessibility.
Sources:
- Yonalink: Clinical trial data streaming, management & more
- Clinical trial data management solutions | Yonalink
- YonaLink Ltd - European Innovation Council
- Increasing Clinical Trial Diversity with a Satellite Model
- Opportunities Amidst Recent Research Policy Challenges
Do you need EIC Accelerator support?
Here is a list of the key service options for the EIC Accelerator:
Full Writing Service
All proposal sections are written by Stephan Segler, PhD.
Advisory Service
You write in-house but receive 1-on-1 support, templates, instructions, and reviews of all documents.
AI Writer & Training
A high-quality AI writer for EIC Accelerator Step 1 and a comprehensive Training program for Steps 1 and 2 including all templates and instructions.